Copyright © 2020, Diaceutics. All rights reserved
Precision Medicine Readiness Report 2020 NSCLC: An Axis for Change
The second Report in our Axis for Change series analyzes the broken diagnostic testing ecosystem impeding the delivery of precision medicines today and recommends a collaborative industry solution
The Problem
A lack of collaboration between precision medicine stakeholders has led to a broken testing ecosystem with only 50% of eligible patients in oncology getting access to the right treatment
.
The Solution
Diaceutics’ Network solution has been purpose built to solve the broken testing ecosystem by enabling the industry-wide collaboration needed to get every patient the treatment they deserve
How a global Network solution has the potential to unlock significantly superior value from precision medicines by accelerating time to peak prescribing of treatments through:
Facilitating CDx partnerships and collaborations in real time enabling treatments to get to market faster
Removing local and regional restrictions to test adoption through access to a global network of implementation partners
Providing in-lab education, external quality assessment (EQA) support, and training to prepare labs for biomarker tests coming to market
Managing Dx quality and inter-lab variability, increasing the cumulative number of patients testing positive
Unlocking access to the world’s largest repository of diagnostic testing data from 2500+ labs in 51 countries to inform better treatment decisions
In the Report you'll gain insights into
The precision tests are ready and available. But a broken clinical diagnostic testing ecosystem has isolated stakeholders along the patient diagnostic pathway and stunted the delivery of innovative Precision Medicine (PM). The DXRX Network helps deliver PM innovation to patients in a streamlined, timely manner. So “emerging” biomarkers become “actionable” biomarkers in time to save more lives than ever before.
NSCLC biomarker testing: today and tomorrow
Reference: Diaceutics Data on File: Diaceutics' proprietary Global Diagnostic Index (GDI) unpublished data, 2020.
To view the entire graphic, reserve Diaceutics' new Pharma PM Readiness Report 2020: NSCLC - An Axis for Change
DXRX - The world's first Diagnostic Network
An end-to-end solution for the development and commercialization of precision medicine diagnostics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.
About Diaceutics
